Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E105.03 EPS (ttm)2.43 Insider Own2.30% Shs Outstand339.50M Perf Week6.83%
Market Cap86.65B Forward P/E16.23 EPS next Y15.73 Insider Trans-36.03% Shs Float334.46M Perf Month15.85%
Income831.00M PEG3.83 EPS next Q2.86 Inst Own66.80% Short Float1.17% Perf Quarter19.23%
Sales9.26B P/S9.36 EPS this Y198.90% Inst Trans20.80% Short Ratio2.35 Perf Half Y58.93%
Book/sh19.16 P/B13.32 EPS next Y40.96% ROA3.40% Target Price52.38 Perf Year106.33%
Cash/sh5.49 P/C46.48 EPS next 5Y27.41% ROE18.20% 52W Range106.00 - 259.99 Perf YTD78.35%
Dividend- P/FCF48.26 EPS past 5Y19.20% ROI8.40% 52W High-3.13% Beta1.09
Dividend %- Quick Ratio4.90 Sales past 5Y58.70% Gross Margin74.00% 52W Low137.59% ATR6.51
Employees16800 Current Ratio5.20 Sales Q/Q16.20% Oper. Margin32.30% RSI (14)61.51 Volatility2.88% 2.43%
OptionableYes Debt/Eq4.03 EPS Q/Q400.00% Profit Margin10.90% Rel Volume0.82 Prev Close255.23
ShortableYes LT Debt/Eq4.01 EarningsJul 23 BMO Payout0.00% Avg Volume1.66M Price251.85
Recom3.00 SMA205.62% SMA507.22% SMA20035.56% Volume128,380 Change-1.32%
Jul-27-15Reiterated Morgan Stanley Overweight $235 → $284
May-26-15Reiterated RBC Capital Mkts Outperform $249 → $265
Apr-30-15Reiterated UBS Buy $222 → $240
Apr-30-15Reiterated Stifel Buy $230 → $250
Apr-30-15Reiterated RBC Capital Mkts Outperform $239 → $249
Apr-30-15Reiterated Cantor Fitzgerald Buy $222 → $271
Feb-25-15Reiterated CRT Capital Buy $180 → $220
Feb-24-15Reiterated UBS Buy $165 → $222
Feb-24-15Reiterated Stifel Buy $175 → $230
Feb-12-15Reiterated RBC Capital Mkts Outperform $188 → $191
Feb-09-15Initiated Barclays Overweight $200
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Jul-30-15 08:56AM  Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers
01:00AM  Pharming Reports on Financial Results First Half Year 2015 PR Newswire
12:00AM  Tax Savings Drove Valeant, Burger King Deals, Senate Report Says
Jul-29-15 09:00PM  Valeant Tells Congress a Very Different Tax Tale Than Investors
Jul-28-15 06:06AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report
Jul-27-15 06:46PM  Which Big-Cap Stocks Are Defying Market Pressure? at Investor's Business Daily
09:02AM  Morgan Stanley Lifts Target On Valeant From $235 To $284
07:00AM  RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals GlobeNewswire
Jul-24-15 07:14PM  Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market at Investor's Business Daily
01:20PM  Biogen's Big-Volume Plunge Marks End Of 5-Year Run
01:10PM  Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog
Jul-23-15 06:35PM  Valeant Clears Buy Point, Paces Top Medical Stocks at Investor's Business Daily +6.24%
05:50PM  3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates at Investor's Business Daily
05:13PM  Stock Market Today - 07/23/15
02:42PM  Shire Lifts 2015 Guidance On Strong Drug Pipeline at Investor's Business Daily
02:25PM  Dealpolitik: Activism Makes Corporate Governance More Complex at Zoetis at The Wall Street Journal
02:10PM  Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
01:22PM  Valeant 2Q results beat estimates sending stock up
11:27AM  Valeant Passes RBC as Canadas Largest Company by Market Value at Bloomberg
11:11AM  Valeant Pharmaceuticals: All That Deal Making Pays Off? at Barrons.com
10:13AM  Valeant profit beats estimates as U.S. sales stay strong
09:37AM  Valeant Earnings Soar On M&A, Organic Sales Growth at Investor's Business Daily
06:38AM  Valeant Ups Views With Big Quarter at The Wall Street Journal
06:27AM  Valeant reports 2Q loss
06:15AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ
06:12AM  Valeant Pharma revenue rises 34 pct
06:09AM  Valeant Pharmaceuticals Second-Quarter Cash EPS Beats Estimates at Bloomberg
06:00AM  Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results CNW Group
Jul-22-15 04:50PM  Illumina Breaches Key Level On Q2 Sales Miss
02:17PM  Why leading growth stocks point to a higher market at MarketWatch
Jul-21-15 08:37PM  Stock Market Today - 07/21/15
04:20PM  Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog
01:00AM  HAEi Global Access Program for RUCONEST┬« Now Live PR Newswire
Jul-20-15 10:55AM  5 ETFs Soaring to All-Time Highs This Summer - ETF News And Commentary
01:00AM  Pharming Announces US$17 Million (15.6 Million) Straight Debt Financing PR Newswire
Jul-18-15 08:02AM  Move Aside Apple: 8 IBD 50 Stocks With Earnings Due at Investor's Business Daily
08:02AM  6 Big-Cap Drugmakers Reporting Earnings Next Week at Investor's Business Daily
Jul-17-15 06:48PM  Newfound Market Strength Could Benefit These IBD 50 Names at Investor's Business Daily
01:31PM  Valeant Pharmaceuticals International, Inc -- Moody's: Valeant's acquisition of Amoun delays deleveraging at Moody's
09:35AM  Valeant to Buy Egypt's Amoun, Expanding to Mideast at The Wall Street Journal
08:14AM  Valeant to buy Egyptian drugmaker Amoun for about $800 mln
08:08AM  Valeant agrees to buy Egypt's Amoun Pharmaceutical for about $800 mln at MarketWatch
08:00AM  Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical PR Newswire
08:00AM  Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical CNW Group
06:59AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jul-16-15 11:58AM  ADBE supported Valueact in June. Struggles with VRX
Jul-15-15 03:25PM  General Electric, Pfizer Among U.S. Companies With Head Start in Iran at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company - Press Releases
Jul-14-15 06:42PM  UNILENS VISION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Unilens Vision Inc. PR Newswire
05:37PM  4 Health Care Stocks to Watch Out for this Earnings Season - Earnings ESP
04:45PM  Valeant to Buy Unilens Vision to Boost Contact Lens Business - Analyst Blog
Jul-13-15 04:50PM  Eyegate-Valeant Team Up for EGP-437; Share Gains for Both - Analyst Blog
Jul-10-15 08:30AM  EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis GlobeNewswire
Jul-09-15 01:53PM  Is Valeant Ready To Pop, Or Drop?
08:56AM  Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Jul-08-15 06:30PM  Foreign Drugmakers Seen Posting Big Earnings Increases at Investor's Business Daily
02:04PM  Rate Hikes Won't Kill Pharma M&A Boomand These Stocks Could Be Next at Barrons.com
11:17AM  Want to Beat the Market? Take on Some Risk at Investopedia
Jul-06-15 11:30AM  Why These Highly Profitable Companies Abandoned Uncle Sam
11:14AM  Apple Inc. (AAPL), Valeant Pharmaceuticals Intl Inc (VRX) Among Steadfast Capitals Top New Picks at Insider Monkey
Jul-02-15 11:20AM  CANADA STOCKS-TSX rises as investors buy up defensive shares
10:32AM  Canada Stocks Rise a 2nd Day as Oil Climbs After U.S. Jobs Data at Bloomberg
09:30AM  The Zacks Analyst Blog Highlights: Conns, Valeant Pharmaceuticals, Trinseo, Nordic American Tankers and Qiwi - Press Releases
Jul-01-15 12:43PM  Allergan and Valeant: Who'll See the Bigger Benefit from Irritable Bowels? at Barrons.com
10:20AM  Sears, Valeant Pharmaceuticals, Kinder Morgan: 3 Stocks Insiders Love at TheStreet
Jun-30-15 04:40PM  AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog
11:48AM  A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round at Barrons.com
Jun-29-15 01:09PM  3 Health Care M&A Deals and How Billionaire Investors are Playing Them at TheStreet
10:17AM  Billionaire Halvorsen and John Lykouretzos Are Betting On The Same Stocks at Insider Monkey
09:44AM  Why General Electric is One Investment Bank's 'Top Pick' at Barrons.com
Jun-28-15 11:18AM  Zoetis Inc (ZTS) Tumbles After Acquisition Rumors Prove To Be Unfounded at Insider Monkey
Jun-27-15 08:15PM  Acquisition in the Health Care Industry Increased Volatility
Jun-26-15 10:58PM  Valeant Shouldnt Overfarm Deal Field at The Wall Street Journal
06:35PM  BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
04:45PM  Zoetis Loses All Of Thursday's Spike On Valeant Buzz at Investor's Business Daily
01:42PM  How to Trade 3 of the Market's Most Active Stocks at TheStreet
01:10PM  Valeant Shouldn't Overfarm Deal Field at The Wall Street Journal
12:06PM  Zoetis Shares Retreat as Analysts Debate Potential Deal Price at The Wall Street Journal
11:54AM  Valeant, Zoetis Shares in the Dog House on Takeout Speculation at Barrons.com
11:19AM  How a trader made 1,300% of their money in minutes at CNBC
10:08AM  Valeant Pharmaceuticals (VRX) Stock Falls After Zoetis Bid at TheStreet
09:36AM  Zoetis and Valeant: The Bill Ackman Connection at Bloomberg
09:09AM  June 26 Premarket Briefing: 10 Things You Should Know
09:00AM  Zoetis Up as Valeant Rumored to be Interested in Buyout - Analyst Blog
07:38AM  Valeant Pharmaceuticals And Zoetis: A True Mega Deal Is On The Horizon at Forbes
Jun-25-15 09:33PM  Micron, Nike, Zoetis in spotlight at MarketWatch
05:33PM  Micron tanks in after hours as profit slumps; Nike up on earnings at MarketWatch
05:26PM  Canada's Valeant approaches to buy Zoetis: WSJ
04:43PM  Valeant makes takeover approach to Zoetis at MarketWatch
04:31PM  Zoetis (ZTS) Stock Higher in After-Hours Trading After Valeant Takeover Approach at TheStreet
04:30PM  Valeant offers to buy Zoetis - WSJ
04:24PM  Zoetis Shares Surge After Report of Takeover Approach by Valeant at Bloomberg
11:08AM  Bullish Sign: Billionaires Lee Ainslie and Mandel Are Investing In These Stocks at Insider Monkey
Jun-24-15 05:19PM  Canada Stocks, TSX Edge Up Despite Oil-Shorn Economy at Investor's Business Daily
02:25PM  Valeant-Progenics Report NDA Filing for Oral Relistor in US - Analyst Blog
09:42AM  Will Apple Inc. (AAPL) Ever Be Dethroned In Robert Raiffs Portfolio? at Insider Monkey
09:25AM  BioLineRx (BLRX) Shows Strength: Stock Rises 7.4% - Tale of the Tape
08:00AM  Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 PR Newswire
08:00AM  Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 CNW Group
06:30AM  5 Stocks Insiders Love Right Now at TheStreet
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM
Kornwasser LaizerEVP, Company Group ChairmanApr 17Option Exercise0.0045,0000123,377Apr 21 05:46 PM
Mirovsky PavelPresident, EMENAApr 15Option Exercise0.0024,175034,175Apr 17 05:28 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM